Skip to content

Biz News Today

Business News – Direct Source News

  • Home
  • Business News Videos
    • International/National News Videos
  • Directory
  • Links PRs
  • REITS
  • About
  • Contact
    • Sitemap

Bristol Myers Squibb Announces RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Melanoma, Meets Primary Endpoint of Progression-Free Survival

  • Home
  • 2021
  • March
  • 25
  • Bristol Myers Squibb Announces RELATIVITY-047, a Trial Evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in Patients with Previously Untreated Metastatic or Unresectable Melanoma, Meets Primary Endpoint of Progression-Free Survival

Original Source

On March 25, 2021

Post navigation

Previous PostQorvo Accelerates 5G Smartphone Design with RF Fusion20™
Next PostJapan’s Ministry of Health, Labour and Welfare Approves Breyanzi, a New CAR T Cell Therapy

Related Post

May 27, 2022
  • Business News

U.S. Food and Drug Administration Approves Two Opdivo® (nivolumab)-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma

May 27, 2022
  • Business News

NVIDIA Recommends Stockholders Reject ‘Mini-Tender’ Offer by Tutanota LLC

May 27, 2022
  • Business News

Quanta Services Announces Quarterly Cash Dividend

Copyright © All right reserved
Newslist Created By Rise Themes

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219